




**Personal Information** \* CV must be written in English

Title	A personalized cancer vaccine targeting neoepitopes	
Name	Chang-Yuil Kang	
Country	Republic of Korea	
Affiliation	College of Pharmacy, Seoul National University	
E-mail	cykang@snu.ac.kr	

**Curriculum Vitae** \* CV must be written in English

**Education and Training**

1981 - 1987 **Ph.D.** in Immunology (State University of New York at Buffalo, USA)  
 1977 - 1981 **M.S.** in Microbiology/Pharmacy (Seoul National University, Seoul, Korea)  
 1973 - 1977 **B.S.** in Pharmacy (Seoul National University, Seoul, Korea)

**Professional Experiences**

1994 - present **Professor** College of Pharmacy, SNU, Seoul, Korea  
 2007 - 2008 **Editor-in-Chief** Immune Network (An official Journal of the Korean Association of Immunobiologists)  
 2005. Nov. **Secretary General** International cytokine society conference 2005  
 2003 - 2004 **President** The Korean Association of Immunobiologists  
 1987 - 1994 **Scientist I, II, III** IDEC Pharmaceutical Corporation (Currently, Biogen-IDEC), La Jolla, California, USA

**Recent Representative Publications**

1. Activation of NKT cells in an anti-PD-1-resistant tumor model enhances anti-tumor immunity by reinvigorating exhausted CD8 T cells. 2018. Bae EA, Seo HS, Kim BS, Choi JW, Jeon IS, Shin KS, Koh CH, Song BY, Kim IK, Min BS, Han YD, Shin SJ, and **Kang CY**. **Cancer Res.** 2018. Sep. 15; 78(18): 5315-5326.
2. IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours. Seo H, Jeon I, Kim BS, Park M, Bae EA, Song B, Koh CH, Shin KS, Kim IK, Choi K, Oh T, Min J, Min BS, Han YD, Kang SJ, Shin SJ, **Kang CY**. **Nat Communications.** 2017.June. 6; 8: 15776.
3. Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells. Kim IK, Kim BS, Koh CH, Seok JW, Park JS, Shin KS, Bae EA, Lee GE, Jeon H, Cho J, Jung Y, Han D, Kwon BS, Lee HY, Chung Y, **Kang CY**. **Nat Med.** 2015 Sep;21(9):1010-7.
4. Tumor-derived osteopontin suppresses antitumor immunity by promoting extramedullary myelopoiesis. Kim EK, Jeon I, Seo HS, Park YJ, Song B, Lee KA, Jang Y, Chung Y, **Kang CY**. **Cancer Res.** 2014 Nov 15;74(22):6705-16.
5. Tumor microenvironmental conversion of natural killer cells into myeloid-derived suppressor cells. Park YJ, Song B, Kim YS, Kim EK, Lee JM, Lee GE, Kim JO, Kim YJ, Chang WS, **Kang CY**. **Cancer Res.** 2013 Sep 15;73(18):5669-81.